
|Videos|May 18, 2017
Later Line Therapeutic Decisions in Metastatic HCC: Case 2
Later Line Therapeutic Decisions in Metastatic HCC
Advertisement
January 2017
- A 74-year old female with a history of HCV-infection
- Prior treatment with interferon, achieving sustained virologic response
- Had recurrence of HCV
- CT scan showed a 6.5-cm single liver mass with arterial enhancement, venous phase washout, and main portal vein invasion
- ECOG=1
- Child-Pugh A
- Therapy was initiated with sorafenib at 400 BID
- Patient experienced grade 3 hand-foot skin reaction; dose reduction to 400 QD
- Patient experienced grade 3 diarrhea; dose reduction to 400 QOD
April 2017
- Follow-up scans show radiographic progression with lung metastases
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
4
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
5




















